111 related articles for article (PubMed ID: 12195818)
1. Enhanced oral absorption of halofantrine enantiomers after encapsulation in a proliposomal formulation.
Brocks DR; Betageri GV
J Pharm Pharmacol; 2002 Aug; 54(8):1049-53. PubMed ID: 12195818
[TBL] [Abstract][Full Text] [Related]
2. Enhanced oral bioavailability of breviscapine after encapsulation in a liposomal formulation.
Zhong HJ; Deng YJ; Yang BH; Li CL; Du S
Pharmazie; 2005 Jun; 60(6):475-6. PubMed ID: 15997842
[TBL] [Abstract][Full Text] [Related]
3. The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins.
Brocks DR; Wasan KM
J Pharm Sci; 2002 Aug; 91(8):1817-26. PubMed ID: 12115809
[TBL] [Abstract][Full Text] [Related]
4. Intestinal lymphatic transport of halofantrine in rats assessed using a chylomicron flow blocking approach: the influence of polysorbate 60 and 80.
Lind ML; Jacobsen J; Holm R; Müllertz A
Eur J Pharm Sci; 2008 Oct; 35(3):211-8. PubMed ID: 18675904
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devices.
Leite EA; Grabe-Guimarães A; Guimarães HN; Machado-Coelho GL; Barratt G; Mosqueira VC
Life Sci; 2007 Mar; 80(14):1327-34. PubMed ID: 17303179
[TBL] [Abstract][Full Text] [Related]
6. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state.
Humberstone AJ; Porter CJ; Edwards GA; Charman WN
J Pharm Sci; 1998 Aug; 87(8):936-42. PubMed ID: 9687337
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of halofantrine in the rat: stereoselectivity and interspecies comparisons.
Brocks DR; Toni JW
Biopharm Drug Dispos; 1999 Apr; 20(3):165-9. PubMed ID: 10211870
[TBL] [Abstract][Full Text] [Related]
9. Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU.
White KL; Nguyen G; Charman WN; Edwards GA; Faassen WA; Porter CJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):700-9. PubMed ID: 19696095
[TBL] [Abstract][Full Text] [Related]
10. Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: implications for lymphatic transport and absolute bioavailability studies.
Caliph SM; Trevaskis NL; Charman WN; Porter CJ
J Pharm Sci; 2012 Sep; 101(9):3540-6. PubMed ID: 22623170
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective pharmacokinetics of desbutylhalofantrine, a metabolite of halofantrine, in the rat after administration of the racemic metabolite or parent drug.
Brocks DR
Biopharm Drug Dispos; 2000 Dec; 21(9):365-71. PubMed ID: 11523065
[TBL] [Abstract][Full Text] [Related]
12. Formulation dependent pharmacokinetics, bioavailability and renal toxicity of a selective cyclooxygenase-1 inhibitor SC-560 in the rat.
Teng XW; Abu-Mellal AK; Davies NM
J Pharm Pharm Sci; 2003; 6(2):205-10. PubMed ID: 12935431
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective halofantrine and desbutylhalofantrine disposition in the rat: cardiac and plasma concentrations and plasma protein binding.
Brocks DR
Biopharm Drug Dispos; 2002 Jan; 23(1):9-15. PubMed ID: 11891669
[TBL] [Abstract][Full Text] [Related]
14. Does stereoselective lymphatic absorption contribute to the enantioselective pharmacokinetics of halofantrine In Vivo?
Shackleford DM; Porter CJ; Charman WN
Biopharm Drug Dispos; 2003 May; 24(4):153-7. PubMed ID: 12698498
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability assessment of vitamin A self-nanoemulsified drug delivery systems in rats: a comparative study.
Taha E; Ghorab D; Zaghloul AA
Med Princ Pract; 2007; 16(5):355-9. PubMed ID: 17709923
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of halofantrine.
Karbwang J; Na Bangchang K
Clin Pharmacokinet; 1994 Aug; 27(2):104-19. PubMed ID: 7955774
[TBL] [Abstract][Full Text] [Related]
17. Formulation-dependent toxicokinetics explains differences in the GI absorption, bioavailability and acute neurotoxicity of deltamethrin in rats.
Kim KB; Anand SS; Muralidhara S; Kim HJ; Bruckner JV
Toxicology; 2007 May; 234(3):194-202. PubMed ID: 17448586
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.
Ramanathan-Girish S; Catz P; Creek MR; Wu B; Thomas D; Krogstad DJ; De D; Mirsalis JC; Green CE
Int J Toxicol; 2004; 23(3):179-89. PubMed ID: 15204721
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion.
Hao H; Wang G; Cui N; Li J; Xie L; Ding Z
Planta Med; 2006 Nov; 72(14):1311-7. PubMed ID: 17024606
[TBL] [Abstract][Full Text] [Related]
20. Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate.
Aideloje SO; Onyeji CO; Ugwu NC
Eur J Pharm Biopharm; 1998 Nov; 46(3):299-303. PubMed ID: 9885302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
